Affymetrix Inc. announced that Empire Genomics, LLC, has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacturing, use and sales of nucleic acid microarrays and related products and services for comparative genomic hybridization (CGH). The arrays and services may be used for research or diagnostic purposes. Financial details of the license were not disclosed.
“Affymetrix continues to establish mutually beneficial licensing relationships with companies such as Empire Genomics to help stimulate the broad commercialization of genome analysis technologies,” said Alan Sherr, vice president and chief counsel for licensing at Affymetrix.
“This agreement with Affymetrix enables Empire Genomics to bring its innovative genomics platform to market while continuing the advancement of personalized medicine. We fully expect that focusing in the field of copy number variation will lead to the discovery of the genomic causes of multiple diseases, as well as advanced therapeutic treatment strategies,” said Anthony Johnson, president and CEO of Empire Genomics.